Aim: A comparative clinical evaluation of the results of prosthetic treatment with chairside CAD/CAM crowns for molars made from hybrid ceramics VITA Enamic, blocks of feldspatic ceramics VITABlocs Mark II, blocks of leucite glass IPS Empress CAD.
Material And Methods: The study involved 30 patients aged from 19 to 60 years old with defects in hard tissues of molars. For clinical evaluation we used 'Clinical criteria for evaluation of direct and indirect restorations' developed by FDI in 2007, which included the assessment of several aesthetic, functional and biological parameters. We also included 2 additional criteria indicators: the condition of the antagonist tooth and the hygienic condition of the prosthesis in comparison with the hygiene of natural teeth. All patients were randomized into 3 groups of 10 people. After the treatment the clinical quality assessment was carried out in the following time intervals: 30 minutes, 1, 6, 12, 18, 24 months after the fixation of the crown.
Results: Clinical evaluation of the results of prosthetic treatment of 30 patients with chairside CAD/CAM crowns made from three different materials did not reveal any significant difference in the clinical criteria for evaluation of direct and indirect restorations within 24 months.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.17116/stomat20199805172 | DOI Listing |
J Trace Elem Med Biol
January 2025
Department of Pathology, College of Medicine, King Khalid University, Asir 61421, Saudi Arabia; Department of Forensic Medicine and Clinical Toxicology, Mansoura University, Egypt.
Background: Vanadium (VAN) is a significant trace element, but its higher exposure is reported to cause severe organ toxicity. Tectochrysin (TEC) is a naturally derived flavonoid which demonstrates a wide range of pharmacological properties.
Aim: The current study was planned to assess the cardioprotective potential of TEC against VAN induced cardiotoxicity in rats via regulating biochemical, and histological profile.
Sci Total Environ
January 2025
Institute for Marine and Antarctic Studies, University of Tasmania, Hobart, Australia; CSIRO Environment, Hobart, Australia.
Ingestion of plastic can have negative health consequences for wildlife. However, our understanding of the physiological impacts of plastics is limited, often relying on opportunistic sampling. We partnered with Tasmanian Aboriginal seabird harvesters, wildlife rescue clinics, and parks managers, to collect >400 fledgling yula/short-tailed and flesh-footed shearwaters across a spectrum of body conditions.
View Article and Find Full Text PDFLung Cancer
January 2025
Dept. of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada.
Background: Manual extraction of real-world clinical data for research can be time-consuming and prone to error. We assessed the feasibility of using natural language processing (NLP), an AI technique, to automate data extraction for patients with advanced lung cancer (aLC). We assessed the external validity of our NLP-extracted data by comparing our findings to those reported in the literature.
View Article and Find Full Text PDFLung Cancer
January 2025
Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Objectives: The lack of definitive biomarkers presents a significant challenge for chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC). We aimed to identify key genes associated with chemo-immunotherapy efficacy in ES-SCLC through comprehensive gene expression analysis using machine learning (ML).
Methods: A prospective multicenter cohort of patients with ES-SCLC who received first-line chemo-immunotherapy was analyzed.
Drug Metab Pharmacokinet
November 2024
Clinical Research, Drug Development Division, Sumitomo Pharma Co., Ltd., 33-94, Enoki-cho, Suita, Osaka, 564-0053, Japan. Electronic address:
The second-generation antipsychotic blonanserin is a highly selective, full antagonist of dopamine D and D and serotonin 5-HT receptors. It is currently prescribed for patients with schizophrenia in Japan. We aimed to develop a population pharmacokinetic model of oral blonanserin, including data from 12 to 77 years old patients, to assess the covariates that influence blonanserin pharmacokinetics and evaluate appropriate dosage regimens in adolescents versus adults.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!